As with most drug pricing battles, patients yet again are caught in the crossfire.
Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.
You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.
The healthcare marketing group made another major acquisition in the country last month.
Omnicom's healthcare revenue was up 2.7% in Q1
J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.
Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.
The firm hired five senior staff in the past month.
Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.
As Sir Martin clears his desk, PRWeek has collected nine thoughts from the worlds of PR, journalism and agency life on the man, his skills, his temperament, and his future.
Martin Sorrell's resignation as chief executive of WPP could lead to a breakup of the company and spark other major changes.
John Tylee examines how a man who never ran an agency rose to become such a dominant force.
Martin Sorrell has stood down as chief executive of WPP, the company has announced.
WPP's board of directors is set to meet as it awaits the outcome of an investigation into the personal conduct of CEO Martin Sorrell.
FDA investigates unapproved herpes vaccine; DC launches PReP campaign; J&J ordered to pay $80 million in damages in asbestos suit.
She is relocating to Switzerland for the role.
The Facebook CEO did not wilt during this week's marathon Senate session.
U.S. deals through the end of March increased 366% compared with last year.
The pharma giant will take up 15 floors of a new Manhattan skyscraper.
Sonderman had worked at GSW since 2001.
GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.
Alexion buys Wilson in latest pharma deal; Drug performance software company Aetion gets financial backing; Roche stops enrollment in combo study after patient deaths.
Despite the US Congress's lack of insight into Facebook's operations, Mark Zuckerberg's handling of the situation seems to have restored investor confidence in the company.
Read the April 2018 issue in its entirety.
The 2018 MM&M/Publicis Health Diversity Survey is open.
White House to allow states to determine health benefits required by Obamacare; FDA orders Essure sales restrictions; Researchers recommend redefining Alzheimer's.
Turett spent 25 years at Edelman before launching her own firm in 2013.
Gillespie will report to W2O president Jennifer Gottlieb.
The industry is being disrupted and marketers are part of the equation.
WPP's investigation into alleged misconduct by founder and chief executive Sir Martin Sorrell could be concluded by next week, according to reports.
Novartis to buy AveXis; Merck lung cancer drug meets primary goal in trial; "Pharma bro" duo expose more drug pricing flaws.
Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment
Facebook puts hospital patient data project on hold; Pharma companies' spending on advocacy under the microscope; Naloxone made more widely available.
She will lead Nuvo Group's U.S. operations and head marketing globally.
Gottlieb asks for internet providers' help fighting opioid crisis; Ferring acquires Rebiotix; AbbVie reaches deal with Biogen to delay Humira rival.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
Obamacare signup total misses 2017 numbers; Feds warn of "nightmare bacteria"; Lilly, startup reach $473 million deal on diabetes work.
The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?
Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.
Read the March 2018 issue in its entirety.
He spent more than 30 years at the pharmaceutical company.
Celgene COO exits; Study: Most Americans think ACA marketplaces are "collapsing"; Average payments to insurers to increase by more than expected in 2019.
We considered pharma and healthcare ads that, per iSpotTV, started airing no earlier than January 2017.
Following massive strikes by Opdivo and Keytruda, will more supersized campaigns follow?
FDA won't review Alkermes' depression drug; Nature Methods retracts paper on CRISPR; Eli Lilly's new R&D chief plans aggressive strategy.
Caregivers and patients predict how the use of AI will affect them.
Walmart and Humana have started acquisition talks; Blue Cross and Blue Shield says opioids should not be the first treatment option to manage pain
PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs; Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug
Chris Palmer, president of CDM New York, shares his wake-up routine, what he's reading and his dream of owning a record store if he wasn't in the medical marketing field.
Takeda considers Shire acquisition; Rite Aid transfers nearly 2,000 stores to Walgreens; Oscar raises $165 million in latest funding round.
The business unit will be rebranded as EMC K.K.
Mesmerize provides static ad materials at the point-of-care, including physician offices and pharmacies.
GSK to buy out Novartis' stake in consumer healthcare partnership; Aetna to pass on prescription drug rebates to members; California drug price transparency law shows results.
Ablynx drops vobarilizumab; Investors unimpressed by Biohaven migraine drug meeting benchmarks; Trump administration prison anti-opioid push relies on naltrexone.
Omnicom's Velocity and WPP's Neighborhood are new networks supporting J&J.
In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?
Why the drugmaker's partnership with a YouTube star is still getting hits.
GSK yanks bid for Pfizer consumer health business; Latest government spending bill includes more for FDA; Chantix fails teen study.
Schirmer previously led McCann Global Health as president for nearly five years.
Anti-opioid-abuse funding in federal budget bill, healthcare market stabilization out; Redfield tapped to lead CDC; Healthcare companies look to pharma for leadership.
Philip Thomas takes over from Terry Savage.
The council, made up of seasoned pharma execs, will function as consultants to rbb's health clients and health team.
Pharma companies are likely to put up aggressive resistance to the measure, introduced earlier this month.
J&J CFO plans September retirement; GSK pharma chief to turn business towards oncology, immunology; MM&M unveils 2018 list of healthcare transformers, innovation catalysts.
AI's marketing problem: Inflated claims, outsized expectations may actually be slowing AI's move into clinical practice
The potential is real, but companies and technology gurus often speak of machine learning as a catch-all solution. The hype may be slowing AI's incremental growth in healthcare, experts say.
MM&M has announced its annual showcase of executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.
Interpublic Group chairman and chief executive told Advertising Week Europe how he managed to turn an "all white, all male" company into one with 54% female leadership.
Roche's immunotherapy Tecentriq, when combined with a Abraxane-based chemo, decreased the risk of disease worsening or death compared to chemo alone in first-line patients with advanced squamous non-small cell lung cancer; President Trump spoke about using federal prosecutors to sue opioid makers; Trump also vowed to bring down the cost of prescription drugs.
Congress has spent less than a quarter of the $500 million to fight the opioid epidemic; The #MeToo movement is gaining steam in the medical industry; Dr. Robert R. Redfield, a leading AIDS researcher, is the top candidate to lead the Centers for Disease Control and Prevention.
The pace may even pick up again this year.
The research will also cover topics including disease awareness ads.
Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.
MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.
UnitedHealth names Witty as Optum CEO; Gilead R&D chief to exit; Novartis ups chief digital officer to executive committee.
Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.
Health's popularity at SXSW continues to build. Here's our opening weekend wrap-up.
Regeneron, Sanofi cut cost of Praluent for wider coverage; GSK to maintain Advair exclusivity for 2018; 'Right to try' bill introduced in House.
White House quashes Idaho's insurance plans; Voyager reports positive results in clinical trial for Parkinson's drug; Cigna-Express Scripts deal to face long review.
Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.
She was one of the firm's original staffers in 2013.
The NY-based shop is known as BX: Brand Experience Design Group.
Cigna to buy Express Scripts for $52B; Gottlieb says 'rigged' system is keeping drug prices high; Sanofi, Evotec speed up infectious disease research.
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
FDA approves 23andMe breast cancer test, with a warning; Novartis partners with Science 37 on clinical trials using mobile devices; European regulator calls for suspension of Zinbryta.
When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.
He was previously a managing partner at Ogilvy CommonHealth.
Pharma has backed a number of AR-based games for physician learning and marketing. They're meant to complement live learning, but mobile games may do a better job teaching certain skills.
Mesara previously worked in communications for pharma companies AbbVie, Abbott, and Pfizer.
UnitedHealth to pass on rebates to customers; Arkansas adds Medicaid work requirements; American College of Physicians reveals Type 2 diabetes guidelines.
The firm recently brought on SVPs in its Washington and Boston offices.
Dermira likely to shelve experimental acne drug; Biotech companies apply to use Crispr gene-editing tool; Another setback for Santhera's Raxone.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
The results will appear in MM&M's Agency A-to-Z directory, which will appear in the magazine's July issue.
Uber rolls out rides to doctor appointments; Trump calls for federal suit against opioid makers; Biogen, AbbVie pull marketing for Zinbryta.
The firm has named Oliver Caporn and Debra Polkes to new roles.